Ipamorelin and CJC-1295 are the most-prescribed peptide combination in clinical longevity and hormone optimization practices. They work through different mechanisms on the same endpoint — both stimulate growth hormone secretion from the pituitary, but via separate receptor systems that produce additive effects when combined. Understanding why practitioners use them together, and what the human evidence actually supports, requires separating each compound first.
Key Takeaways
- —CJC-1295 DAC has a half-life of 6–8 days; a single injection raises plasma GH 2–10x and IGF-1 0.5–3x for 9–11 days (PubMed, Teichman et al., 2006).
- —Ipamorelin is the first growth hormone secretagogue shown to release GH selectively — even at 200× its effective dose, it did not significantly elevate ACTH or cortisol (PubMed, Raun et al., 1998).
- —The combination works via dual receptor activation: GHRH receptor (CJC-1295) + ghrelin receptor/GHS-R1a (ipamorelin) — producing a synergistic GH pulse.
- —Both compounds carry FDA Category 2 status (2024), prohibiting commercial compounding in the US.
- —Long-term human data beyond 6–12 month studies remains limited.
CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH) — the hypothalamic peptide that signals the pituitary to release GH. The native GHRH molecule has a half-life of only a few minutes in plasma due to dipeptidyl peptidase IV (DPP-IV) cleavage. CJC-1295 introduces amino acid substitutions that resist that enzymatic degradation.
Two versions exist, and the difference between them is clinically significant:
CJC-1295 without DAC (also called Mod GRF 1-29): Half-life of approximately 30 minutes. It produces a sharp, physiological GH pulse when injected, mimicking the natural pulsatile pattern of GHRH release. Dosed 1–2× daily.
CJC-1295 with DAC (Drug Affinity Complex): The DAC modification allows the peptide to bind covalently to albumin in the bloodstream, dramatically extending its half-life to 6–8 days. A single injection of CJC-1295 DAC raises plasma GH levels 2–10x over baseline for 6 or more days and elevates IGF-1 by 0.5–3x for 9–11 days (Teichman et al., JCEM, 2006). This is the only peer-reviewed human pharmacokinetic study on CJC-1295 DAC.
The choice between DAC and non-DAC has real protocol implications. Weekly DAC injections are convenient but produce non-pulsatile GH elevation. Daily non-DAC injections are more burdensome but maintain the rhythmic pattern of natural GH secretion, which may matter for avoiding desensitization of pituitary receptors.
Ipamorelin is a pentapeptide growth hormone secretagogue — it mimics ghrelin, binding to the GHS-R1a receptor in the pituitary and hypothalamus to trigger GH release. Unlike earlier GHRPs (GHRP-2, GHRP-6), ipamorelin is highly selective.
In the landmark 1998 characterisation study by Raun et al. in Endocrinology, ipamorelin was tested at doses more than 200 times its effective dose for GH release (ED50). At these doses, ACTH and cortisol levels did not differ significantly from those observed with GHRH stimulation alone (PubMed, 1998). This contrasted sharply with GHRP-2 and GHRP-6, which produced significant cortisol and ACTH elevation — side effects that limit their clinical usefulness.
Ipamorelin also doesn't meaningfully increase prolactin or cause the appetite stimulation associated with ghrelin itself. This selectivity profile — GH release without the off-target hormonal cascade — is the primary reason ipamorelin became the GHRP of choice for clinical stacking.
The half-life of ipamorelin is approximately 2 hours. It produces a short, sharp GH pulse that declines over 3–4 hours. When combined with a GHRH analogue like CJC-1295, the two mechanisms produce a larger, more sustained GH release than either achieves alone.
The pituitary gland releases GH when stimulated by two inputs:
CJC-1295 acts on the first receptor. Ipamorelin acts on the second. When both receptors are activated simultaneously, GH release is synergistic — greater than the sum of the individual stimuli. This is the pharmacological rationale for the combination.
According to the 2006 phase II study by Teichman et al. in the Journal of Clinical Endocrinology & Metabolism, multiple CJC-1295 injections produced dose-dependent increases in plasma GH concentrations, with mean GH concentrations increasing by 1.5 to 3.0 fold during 28 days after dosing, and mean IGF-1 concentrations increasing by 1.3 to 1.5 fold (PubMed).
The clinical rationale is to restore the GH secretion pattern associated with younger physiology — not to achieve supraphysiological GH levels, but to raise chronically low GH output toward the range seen in healthy 25–35 year olds.
The human evidence base is thin but not absent.
CJC-1295 DAC pharmacokinetics (Teichman et al., 2006): The only formal phase I/II human study. 65 healthy adults received single or multiple doses of CJC-1295 DAC. Results: dose-dependent GH and IGF-1 elevation with a favourable safety profile. This remains the primary human PK reference for the compound.
Older adults and body composition (2025 study): A 2025 study in older adults receiving combined CJC-1295 / ipamorelin therapy demonstrated significant improvements in lean muscle mass, strength, and physical performance, attributed to optimised GH secretion and improved protein synthesis. Sample sizes were small and the study design varied from site to site — this data is promising but not RCT-grade.
FDA Category 2 submissions (2024): In December 2024, the FDA published submissions on both CJC-1295 and ipamorelin for consideration on the 503A bulk compounding list. Both were denied Category 1 (safe to compound) status based on insufficient human safety and efficacy data at proposed doses. This doesn't mean the compounds are unsafe — it means the evidence is insufficient for FDA to sanction compounding.
These protocols reflect clinical practice patterns and extrapolation from preclinical and limited human data — not FDA-approved indications.
| Protocol | CJC-1295 Dose | Ipamorelin Dose | Frequency |
|---|---|---|---|
| Conservative | 100 mcg (no DAC) | 200 mcg | Daily before sleep |
| Standard | 200 mcg (no DAC) | 300 mcg | Twice daily |
| Convenience (DAC) | 1–2 mg (with DAC) | 200–300 mcg | Weekly + daily |
IGF-1 is the primary surrogate marker for GH axis activity. Practitioners typically check baseline IGF-1, then re-test at 6–8 weeks. Target range in clinical GH optimisation is usually the upper quartile of the age-adjusted normal range — not supraphysiological.
Elevated IGF-1 warrants dose reduction. Sustained supraphysiological IGF-1 is associated with increased cell proliferation rates and is theoretically linked to cancer risk — the same concern applies to exogenous rhGH at pharmacological doses.
Other parameters to monitor: fasting glucose (GH is counter-regulatory to insulin), thyroid function (GH influences T4→T3 conversion), and cortisol (relevant with GHRPs that may elevate it — less of a concern with selective ipamorelin).
Neither compound is FDA-approved for any therapeutic use. Both are Category 2 bulk drug substances as of 2024. They are not controlled substances, but cannot be legally compounded commercially. WADA prohibits both in sport.
The clinical safety profile over short to medium term (6–12 months) is described as acceptable in available data, with the most common adverse effects being injection site reactions, headache, and transient fluid retention. Long-term safety data (>1 year) in healthy adults is not available from published RCTs.
The ipamorelin research profile on Next Pep covers the GHS-R1a mechanism, the Teichman 2006 phase I/II human data, pharmacokinetics, and the DAC vs non-DAC distinction in a single cross-referenced view. Before you evaluate any vendor, this is the objective baseline that separates what the evidence actually shows from what product listings claim.
Use the comparison tool to put ipamorelin and CJC-1295 alongside sermorelin or other GH secretagogues — comparing half-life, human trial data, and regulatory status side-by-side. The dosing calculator handles the reconstitution maths for both compounds: enter your vial concentration and target dose and it returns exact draw volume in mL and syringe units. And Next Pep's peptide library covers the full GH secretagogue class so you can verify which compound fits your specific research application.
The combination stimulates pituitary growth hormone secretion through two separate receptor pathways (GHRH receptor and ghrelin receptor/GHS-R1a), producing an additive GH pulse. The practical downstream effects studied include improved body composition (lean mass, fat mass), sleep quality, and recovery — though human RCT evidence for these endpoints is limited.
CJC-1295 without DAC (Mod GRF 1-29) has a 30-minute half-life and produces a short, pulsatile GH release — more similar to natural GHRH. CJC-1295 with DAC has a 6–8 day half-life (due to albumin binding) and produces sustained GH elevation for 6+ days per injection. Most practitioners prefer without-DAC to preserve pulsatile signaling.
Both are FDA Category 2 (2024), meaning they cannot be commercially compounded in the US. They are not controlled substances — personal possession isn't illegal — but they exist in a regulatory grey zone. Both are WADA-prohibited in competitive sport.
The standard monitoring approach is IGF-1 testing at baseline and 6–8 weeks into a protocol. IGF-1 should remain within the upper quartile of the age-adjusted reference range, not supraphysiological. Fasting glucose, thyroid function, and cortisol are sometimes monitored depending on the clinical context.
Based on the available human pharmacokinetic data and clinical reports, IGF-1 elevation is measurable within 2–4 weeks. Subjective changes in body composition, sleep, and recovery are typically reported at 6–12 weeks. These timelines are consistent with how GH-axis changes manifest structurally, but come from clinical practice observations, not controlled human trials.
This article is for research and educational purposes only. Neither ipamorelin nor CJC-1295 is FDA-approved for human therapeutic use. Consult a licensed healthcare professional before considering any peptide protocol.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
A head-to-head comparison of BPC-157 and TB-500 covering mechanism, tissue specificity, dosing frequency, human evidence, and whether stacking them adds anything the literature actually supports.
Ipamorelin is a ghrelin-receptor agonist; CJC-1295 is a GHRH analog. Their mechanisms are complementary, which is why protocols typically stack them. This guide covers what each does alone, what stacking adds, and the DAC vs non-DAC distinction.